Few companies in health care are as diversified as giant Johnson & Johnson. That's a big reason it turned in a stellar overall performance despite some problem areas. Sales of J&J's biggest drug, the $2.8 billion anemia treatment Procrit, slipped 8% in 2003 due to tough competition. But other products, like the arthritis drug Remicade, posted big gains. And J&J's revolutionary new drug-coated stent took the market by storm. That helped boost 2003 sales by 15%. Still, J&J faces tough headwinds, including a challenge to its stent franchise from rival Boston Scientific.